When the dose is too low, there is little or no 'clinical benefit'. But, if the dose is greater than 'optimal', what happens? Is it just diminishing returns? Is there simply no improvement past a certain point? Does the benefit vs. dose curve level off, approach an asymptote?
Or, is there a reduction in 'clinical benefit' when the dose is greater than optimal? Is the benefits vs. dose curve a bell curve?
[Modified by: subtle on July 13, 2007 01:06 PM]